A comparison of liposomal formulations of doxorubicin with Drug Administered in free form: Changing toxicity profiles

Drug Safety

Volumn 24, Issue 12, 2001, Pages 903-920

  Waterhouse, Dawn N ^a,b   Tardi, Paul G ^b   Mayer, Lawrence D ^a,b   Bally, Marcel B ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; BLEOMYCIN; CARDIOLIPIN; CHOLESTEROL; CYCLOPHOSPHAMIDE; DIGITALIS; DIGOXIN; DOXORUBICIN; EVACET; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRON CHELATE; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NAVELBINE; OCTADECYLAMINE; PACLITAXEL; PHOSPHATIDYLCHOLINE; RAZOXANE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOMYOPATHY; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG STRUCTURE; DYSESTHESIA; GASTROINTESTINAL TOXICITY; HUMAN; KAPOSI SARCOMA; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DOXORUBICIN; DRUG COMBINATIONS; FEMALE; HUMANS; LIPOSOMES; OVARIAN NEOPLASMS;

EID: 0035164058     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124120-00004     Document Type: Review

References (66)

1. In vitro and in vivo studies with adriamycin liposomes
2. Liposomal protection of adriamycin-induced cardiotoxicity in mice
3. Anthracyclines in the treatment of cancer: An overview
4. Pathogenesis prevention of doxorubicin cardiomyopathy
5. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity
6. Strategies for reduction of anthracycline cardiac toxicity
7. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
8. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy
9. Doxorubicin-induced cardiomyopathy
10. Prolonged circulation time enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
11. Drug data sheets, doxorubicin
12. Pharmacology of adriamycin: The message to the clinician
13. Development of liposomal anthracyclines: From basics to clinical applications
14. Liposomal Doxorubicin
15. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins
16. Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoprotein
17. In vivo recognition and clearance of red blood cells containing phosphatidlyserine in their plasma membranes
18. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin
19. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages
20. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
21. An improved method of encapsulation of doxorubicin in lipsomes: Pharmacological, toxicological and therapeutic evaluation
22. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study
23. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)
24. Phase I study of doxorubicin encapsulated in liposomes
25. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs
26. Controlling liposome blood clearance by surface-grafted polymers
27. Sterically stabilized liposomes: Physical and biological properties
28. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours
29. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
30. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
31. Doxil (Caelyx): An exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
32. Phase I/II study of liposome encapsulated doxorubicin (TLC D-99) in non-small cell lung cancer (NSCLC)
33. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma
34. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin
35. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
36. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
37. AIDS-related Kaposi's sarcoma: A phase II study of liposomal doxorubicin
38. Caelyx (Doxil;liposomal doxorubicin) is tolerated well long-term at high cumulative dose in AIDS-related Kaposi's sarcoma (AIDS-KS) patients: A meta-analysis of 1716 patients
39. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
40. Pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HCC)
41. Clinical efficacy and toxicity of standard dose adraimycin in hyperbilirubinaemic patients with hepatocellular carcinoma: Relation to liver tests and pharmacokinetic parameters
42. 2
43. New developments in chemotherapy of advanced breast cancer
44. Cancer of the breast: The past decade
45. Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer
46. Unexpected low efficacy of Caelyx Vinorelbine in metastatic breast cancer (MBC)
47. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide and fluorouracil as first-line therapy in patients with metastatic breast cancer
48. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
49. Doxorubicin (A)/taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study
50. Reduced cardiotoxicity of liposome-encapsulated doxorubicin (TLC D-99) compared to free doxorubicin in first-line therapy of metastatic breast cancer in patients at increased risk for anthracycline-induced cardiac toxicity
51. Improved therapeutic index of TLC D-99 (liposome-encapsulated doxorubicin) compared to free doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin
52. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer
53. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
54. HER-2/neu oncogene protein and prognosis in breast cancer
55. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
56. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
57. Phase II study of liposomal doxorubicin in advanced gynecologic cancers
58. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
59. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
60. A phase II and pharmacokinetic/dynamic study of Doxil and weekly paclitaxel chemotherapy for recurrent mullerian tumors
61. Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer
62. Doxorubicin/Taxane combinations: Cardiac toxicity and Pharmacokinetics